Literature DB >> 19288013

Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival.

Alastair G W Moses1, Jean Maingay, Kathryn Sangster, Kenneth C H Fearon, James A Ross.   

Abstract

The acute phase protein response (APPR) and peripheral blood mononuclear cell-derived inflammatory cytokine production was assessed in patients with advanced pancreatic cancer and age-matched healthy volunteers. We examined the relationship between the APPR, cytokine production and survival in these patients. Forty-two patients with pancreatic cancer cachexia and twelve age-matched healthy controls were recruited. The nutritional status, Karnofsky performance score, C reactive protein (CRP), serum interleukin-6, and in vitro monocyte interleukin-1 and interleukin-6 production were measured. The dates of death of the pancreatic cancer patients were subsequently obtained and appropriate patient variables at baseline were entered into a Cox's proportional hazards model. The cancer patients had significantly lower: body mass index, Karnofsky performance score, serum albumin and elevated CRP and stimulated interleukin-6 production. Both univariate and multivariate analysis demonstrated a strong association between tumour stage, CRP, stimulated interleukin-6 production and survival. Monocytes in cachectic pancreatic cancer patients are primed to produce high levels of interleukin-6 when stimulated. Overproduction of interleukin-6 has a negative impact on survival. Decreased survival is associated with an elevated APPR. While the elevated APPR is probably related to locally produced interleukin-6 in the liver, it seems possible that locally and systemically produced interleukin-6 influences survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288013     DOI: 10.3892/or_00000328

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  46 in total

1.  The effect of resistance exercise on all-cause mortality in cancer survivors.

Authors:  Justin P Hardee; Ryan R Porter; Xuemei Sui; Edward Archer; I-Min Lee; Carl J Lavie; Steven N Blair
Journal:  Mayo Clin Proc       Date:  2014-06-21       Impact factor: 7.616

2.  Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Spas D Markov; Kuldeep S Attri; Enza Vernucci; Ryan J King; Aneesha Dasgupta; Paul M Grandgenett; Michael A Hollingsworth; Pankaj K Singh; Fang Yu; Kamiya Mehla
Journal:  Cancer Lett       Date:  2020-04-25       Impact factor: 8.679

3.  Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer.

Authors:  Sang-Yeon Suh; Youn Seon Choi; Chang Hwan Yeom; Sang Mi Kwak; Ho Min Yoon; Dae Gyun Kim; Su-Jin Koh; Jeanno Park; Myung Ah Lee; Yong Joo Lee; Ah-Ram Seo; Hong-Yup Ahn; Eunji Yim
Journal:  Support Care Cancer       Date:  2013-07-05       Impact factor: 3.603

4.  Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia.

Authors:  Jeong Min An; Eun A Kang; Young-Min Han; Ji Young Oh; Dong Yoon Lee; Seung Hye Choi; Duk Hwan Kim; Ki Baik Hahm
Journal:  J Clin Biochem Nutr       Date:  2019-07-27       Impact factor: 3.114

5.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

6.  Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.

Authors:  Michael Haas; Volker Heinemann; Frank Kullmann; Rüdiger P Laubender; Christina Klose; Christiane J Bruns; Stefan Holdenrieder; Dominik P Modest; Christoph Schulz; Stefan Boeck
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-13       Impact factor: 4.553

Review 7.  Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.

Authors:  Alessandro Paniccia; Justin Merkow; Barish H Edil; Yuwen Zhu
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

8.  Assessment of p38α in peripheral blood mononuclear cells (PBMC): a potential blood protein marker of head and neck squamous cell carcinoma.

Authors:  K Gill; R Kumar; B Kalyan Mohanti; S Dey
Journal:  Clin Transl Oncol       Date:  2013-04-04       Impact factor: 3.405

Review 9.  Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.

Authors:  Jawed A Siddiqui; Ramesh Pothuraju; Maneesh Jain; Surinder K Batra; Mohd W Nasser
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-03-25       Impact factor: 10.680

10.  Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts.

Authors:  Ying Bao; Edward L Giovannucci; Peter Kraft; Zhi Rong Qian; Chen Wu; Shuji Ogino; J Michael Gaziano; Meir J Stampfer; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Michael N Pollak; Li Jiao; Lawrence Lessin; Barbara B Cochrane; Joann E Manson; Charles S Fuchs; Brian M Wolpin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.